Asahi shares mark weekly slide after cyberattack halts production
Investing.com - Evercore ISI downgraded BioCryst Pharmaceuticals (NASDAQ:BCRX) from Outperform to In Line and lowered its price target to $8.00 from $12.00 on Wednesday. The company, currently trading at $7.59, shows strong revenue growth of 46% over the last twelve months, according to InvestingPro data, which indicates the stock may be undervalued at current levels.
The research firm cited increasing competition in the hereditary angioedema (HAE) treatment landscape as the primary reason for the downgrade, describing the situation as a "zero-sum" scenario where BioCryst’s Orladeyo is not positioned to be a market leader. With a healthy gross profit margin of 66.5% and current ratio of 2.25, InvestingPro analysis shows the company maintains strong financial fundamentals despite competitive pressures.
Evercore ISI projects Orladeyo will capture approximately 25% of peak long-term prophylaxis market share by 2028, generating around $700 million in U.S. sales, below the consensus estimate of $800-900 million.
The firm expects this market share to steadily decline to approximately 14% over the following decade due to "fierce competition" in the HAE treatment space, though it noted the product should still maintain "nice longevity."
In its revised valuation model focusing primarily on Orladeyo, Evercore ISI arrived at an $8 per share year-end 2026 price target, representing approximately 2.6 times peak sales, while noting BioCryst’s projected strong cash position could potentially lead to business development activities. InvestingPro analysis reveals additional insights through 8+ exclusive ProTips and comprehensive financial metrics, available in the detailed Pro Research Report covering BCRX and 1,400+ other top stocks.
In other recent news, BioCryst Pharmaceuticals reported a remarkable earnings performance for the second quarter of 2025. The company achieved earnings per share of $0.15, significantly surpassing the forecasted $0.01, resulting in a 1400% earnings surprise. Additionally, BioCryst’s revenue reached $163.4 million, exceeding the anticipated $149.82 million, showcasing strong financial results. In a strategic move, BioCryst completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with potential additional milestone payments of up to $14 million. This transaction allows BioCryst to concentrate on its U.S. market while Neopharmed Gentili takes over European commercialization. Furthermore, BioCryst announced the departure of Dr. Helen Thackray, its chief research and development officer, who will transition to an advisory role before pursuing a CEO position elsewhere. These developments reflect BioCryst’s ongoing strategic adjustments and leadership transitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.